Literature DB >> 30894098

Structural basis of drug recognition by human serum albumin.

Loris Leboffe1, Alessandra di Masi1, Fabio Polticelli1, Viviana Trezza1, Paolo Ascenzi2.   

Abstract

BACKGROUND: Human serum albumin (HSA), the most abundant protein in plasma, is a monomeric multi-domain macromolecule with nine observed binding sites for endogenous and exogenous ligands. HSA displays an extraordinary ligand binding capacity as a depot and carrier for many compounds including most acidic drugs. Consequently, HSA has the potential to influence the pharmacokinetics and pharmacodynamics of drugs.
OBJECTIVE: In this review, the structural determinants of drugs binding mode to all the multiple sites of HSA has been analyzed and discussed in detail. Moreover, insight into the allosteric and competitive mechanisms underpinning drug recognition, delivery, and efficacy have been analyzed and discussed.
CONCLUSION: As several factors can modulate drug binding to HSA (e.g., concurrent administration of drugs competing for the same binding site, ligand binding to allosteric-coupled clefts, genetic inherited diseases, pathological conditions, and age) the modulation of ligand binding to HSA is relevant not only under physiological conditions, but also in the pharmacological therapy management.  . Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  human serum albumin; drug carrier; drug recognition; structural basis; allosteric modulation of drug binding; competitive modulation of drug binding.

Year:  2019        PMID: 30894098     DOI: 10.2174/0929867326666190320105316

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  6 in total

1.  Novel Albumin Nanoparticle Enhanced the Anti-Insulin-Resistant-Hepatoma Activity of Metformin.

Authors:  Zhong Lu; Li Qi; Ya-Ru Lin; Lei Sun; Lin Zhang; Gui-Chun Wang; Jia-Qiu Li; Jin-Ming Yu
Journal:  Int J Nanomedicine       Date:  2020-07-23

2.  Using Human Serum Albumin Binding Affinities as a Proactive Strategy to Affect the Pharmacodynamics and Pharmacokinetics of Preclinical Drug Candidates.

Authors:  Jianwei Fan; Katherine Gilmartin; Steven Octaviano; Francisca Villar; Brianna Remache; John Regan
Journal:  ACS Pharmacol Transl Sci       Date:  2022-08-16

Review 3.  Clinical Significance of Serum Albumin and Implications of FcRn Inhibitor Treatment in IgG-Mediated Autoimmune Disorders.

Authors:  E Sally Ward; Deborah Gelinas; Erwin Dreesen; Jolien Van Santbergen; Jan Terje Andersen; Nicholas J Silvestri; Joseph E Kiss; Darrell Sleep; Daniel J Rader; John J P Kastelein; Els Louagie; Gestur Vidarsson; Isabel Spriet
Journal:  Front Immunol       Date:  2022-06-01       Impact factor: 8.786

4.  Development of a caffeic acid-phthalimide hybrid compound for NADPH oxidase inhibition.

Authors:  Willian Henrique Dos Santos; Maurício Ikeda Yoguim; Regina Gomes Daré; Luiz Carlos da Silva-Filho; Sueli Oliveira Silva Lautenschlager; Valdecir Farias Ximenes
Journal:  RSC Adv       Date:  2021-05-18       Impact factor: 4.036

5.  Human Serum Albumin Facilitates Heme-Iron Utilization by Fungi.

Authors:  Mariel Pinsky; Udita Roy; Shilat Moshe; Ziva Weissman; Daniel Kornitzer
Journal:  mBio       Date:  2020-04-21       Impact factor: 7.867

6.  Ruxolitinib binding to human serum albumin: bioinformatics, biochemical and functional characterization in JAK2V617F+ cell models.

Authors:  Elisabetta De Marinis; Alessia Ceccherelli; Alberto Quattrocchi; Loris Leboffe; Fabio Polticelli; Clara Nervi; Paolo Ascenzi
Journal:  Sci Rep       Date:  2019-11-08       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.